Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells

European Journal of Cancer

Volumn 36, Issue 14, 2000, Pages 1863-1868

  Takahashi, M ^a   Kigawa, J ^a   Minagawa, Y ^a   Itamochi, H ^a   Shimada, M ^a   Kamazawa, S ^a   Sato, S ^a   Akeshima, R ^a   Terakawa, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cisplatin; Ovarian cancer; Paclitaxel; TP53 gene

Indexed keywords

CISPLATIN; PACLITAXEL; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN CELL; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, P53; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0033895708     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00183-0     Document Type: Article

References (34)

1. Muggia F.M. Cisplatin update. Semin. Oncol. 18:1991;1-4.
2. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA. 89:1992;3070-3074.
3. Andrews P.A., Velury S., Mann S.C., Howell S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48:1988;68-73.
4. Andrews P.A., Howell S.B. Cellular pharmacology of cisplatin. perspectives on mechanisms of acquired resistance Cancer Cells. 2:1990;35-43.
5. Fujiwara Y., Sugimoto Y., Kasahara K.et al. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn. J. Cancer Res. 81:1990;527-535.
6. Kasahara K., Fujiwara Y., Nishio K.et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 51:1991;3237-3242.
7. Masuda H., Ozols R.F., Lai G.M., Fojo A., Rothenberg M., Hamilton T.C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48:1988;5713-5716.
8. Minagawa Y., Kigawa J., Ishihara H., Itamochi H., Terakawa N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn. J. Cancer Res. 85:1994;966-971.
9. Righetti S.C., Della Torre G., Pilotti S.et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:1996;689-693.
10. Minagawa Y., Kigawa J., Itamochi H.et al. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn. J. Cancer Res. 90:1999;1973-1979.
11. Williams G.T., Smith C.A. Molecular regulation of apoptosis. genetic controls on cell death Cell. 74:1993;777-779.
12. Lu S.J., Man S., Bani M.R.et al. Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance. Cancer Res. 55:1995;1139-1145.
13. Kastan M.B., Canman C.E., Leonard C.J. p53, cell cycle control and apoptosis. implications for cancer Cancer Metastasis Rev. 14:1995;3-15.
14. Kanamori Y., Kigawa J., Minagawa Y.et al. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur. J. Cancer. 34:1998;1802-1806.
15. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
16. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
17. Boise L.H., Gonzalez-Garcia M., Postema C.E.et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
18. Marone M., Scambia G., Mozzetti S.et al. bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin. Cancer Res. 4:1998;517-524.
19. Henriksen R., Wilander E., Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br. J. Cancer. 72:1995;1324-1329.
20. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA. 77:1980;1561-1565.
21. Kelland L.R., Abel G. Comparative in vitro cytotoxicity of taxol and Taxotereovarian cancer against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 30:1992;444-450.
22. Wu G.S., El-Diery W.S. p53 and chemosensitivity. Nature Med. 2:1996;255-256.
23. Debernardis D., Sire E.G., De Feudis P.et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 57:1997;870-874.
24. Graniela Sire E.A., Vikhanskaya F., Broggini M. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann. Oncol. 6:1995;589-593.
25. Wahl A.F., Donaldson K.L., Fairchild C.et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 2:1996;72-79.
26. Vikhanskaya F., Vignati S., Beccaglia P.et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp. Cell. Res. 241:1998;96-101.
27. Eastman A. Activation of programmed cell death by anticancer agents. cisplatin as a model system Cancer Cells. 2:1990;275-280.
28. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1:1995;506-526.
29. O'Connor P.M., Jackman J., Bae I.et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
30. Liu J.R., Fletcher B., Page C., Hu C., Nunez G., Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70:1998;398-403.
31. Strobel T., Kraeft S.K., Chen L.B., Cannistra S.A. BAX expression is associated with enhanced intracellular accumulation of paclitaxel. a novel role for BAX during chemotherapy-induced cell death Cancer Res. 58:1998;4776-4781.
32. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4:1998;835-846.
33. Irie T., Kigawa J., Minagawa Y.et al. Alteration of p53 gene status affects outcome of patients with recurrent ovarian cancer. Oncology. 58:2000;237-241.
34. Sato S., Kigawa J., Minagawa Y.et al. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer. 86:1999;1307-1313.